C
Chung-Han Lee
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 102
Citations - 4893
Chung-Han Lee is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 20, co-authored 68 publications receiving 2865 citations. Previous affiliations of Chung-Han Lee include Cornell University & University of Michigan.
Papers
More filters
Journal ArticleDOI
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M. Samstein,Chung-Han Lee,Chung-Han Lee,Alexander N. Shoushtari,Alexander N. Shoushtari,Matthew D. Hellmann,Matthew D. Hellmann,Ronglai Shen,Yelena Y. Janjigian,Yelena Y. Janjigian,David Barron,Ahmet Zehir,Emmet Jordan,Antonio Omuro,Thomas Kaley,Sviatoslav M. Kendall,Robert J. Motzer,Robert J. Motzer,A. Ari Hakimi,Martin H. Voss,Martin H. Voss,Paul Russo,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Gopa Iyer,Gopa Iyer,Bernard H. Bochner,Dean F. Bajorin,Dean F. Bajorin,Hikmat Al-Ahmadie,Jamie E. Chaft,Jamie E. Chaft,Charles M. Rudin,Charles M. Rudin,Gregory J. Riely,Gregory J. Riely,Shrujal S. Baxi,Shrujal S. Baxi,Alan L. Ho,Alan L. Ho,Richard J. Wong,David G. Pfister,David G. Pfister,Jedd D. Wolchok,Jedd D. Wolchok,Christopher A. Barker,Philip H. Gutin,Cameron Brennan,Viviane Tabar,Ingo K. Mellinghoff,Lisa M. DeAngelis,Charlotte E. Ariyan,Nancy Y. Lee,William D. Tap,William D. Tap,Mrinal M. Gounder,Mrinal M. Gounder,Sandra P. D'Angelo,Sandra P. D'Angelo,Leonard B. Saltz,Leonard B. Saltz,Zsofia K. Stadler,Zsofia K. Stadler,Howard I. Scher,Howard I. Scher,José Baselga,José Baselga,Pedram Razavi,Pedram Razavi,Christopher A. Klebanoff,Christopher A. Klebanoff,Rona Yaeger,Rona Yaeger,Neil H. Segal,Neil H. Segal,Geoffrey Y. Ku,Geoffrey Y. Ku,Ronald P. DeMatteo,Marc Ladanyi,Naiyer A. Rizvi,Michael F. Berger,Nadeem Riaz,David B. Solit,Timothy A. Chan,Luc G. T. Morris +84 more
TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Journal ArticleDOI
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
A. Ari Hakimi,Ed Reznik,Chung-Han Lee,Chad J. Creighton,A. Rose Brannon,Augustin Luna,B. Arman Aksoy,Eric Minwei Liu,Ronglai Shen,William Lee,Yang Chen,Steve Stirdivant,Paul Russo,Ying-Bei Chen,Satish K. Tickoo,Victor E. Reuter,Emily H. Cheng,Chris Sander,James J. Hsieh,James J. Hsieh +19 more
TL;DR: An analytic pipeline and visualization tool (metabolograms) is developed to bridge the gap between TCGA transcriptomic profiling and metabolomic data, which enables to assemble an integrated pathway-level metabolic atlas and to demonstrate discordance between transcriptome and metabolome.
Journal ArticleDOI
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor,Chung-Han Lee,Vicky Makker,Drew W. Rasco,Corina E. Dutcus,Jane Wu,Daniel E. Stepan,Robert Shumaker,Robert J. Motzer +8 more
TL;DR: Lenvatinib plus pembrolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with selected solid tumor types.
Journal ArticleDOI
mTOR Pathway as a Target in Tissue Hypertrophy
TL;DR: The mTOR pathway involves two functional complexes, TORC1 and TORC2, which have been defined by both their association with raptor or rictor, respectively, and their sensitivity to short-term rapamycin inhibition.
Journal ArticleDOI
Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53.
Chung-Han Lee,Ken Inoki,Magdalena Karbowniczek,Emmanuel Petroulakis,Nahum Sonenberg,Elizabeth P. Henske,Kun-Liang Guan +6 more
TL;DR: The coordinated relationship between mTOR and p53 during cellular stress provides a possible explanation for the benign nature of hamartoma syndromes, including TSC, and suggests that the efficacy of mTOR inhibitors in anti‐neoplastic therapy may also depend on p53 status, and m TOR inhibitors may antagonize the effects of genotoxic chemotherapeutics.